Literature DB >> 25065371

In vivo HIV-1 hypermutation and viral loads among antiretroviral-naive Brazilian patients.

Mariana Leão de Lima-Stein1, Wagner Tadeu Alkmim, Maria Clara de Souza Bizinoto, Luis Fernandez Lopez, Marcelo Nascimento Burattini, Juliana Terzi Maricato, Leila Giron, Maria Cecília Araripe Sucupira, Ricardo Sobhie Diaz, Luiz Mario Janini.   

Abstract

Hypermutation alludes to an excessive number of specific guanine-to-adenine (G- >A) substitutions in proviral DNA and this phenomenon is attributed to the catalytic activity of cellular APOBECs. Population studies relating hypermutation and the progression of infection by human immunodeficiency virus type 1 (HIV-1) have been performed to elucidate the effect of hypermutation on the natural course of HIV-1 infection. However, the many different approaches employed to assess hypermutation in nucleotide sequences render the comparison of results difficult. This study selected 157 treatment-naive patients and sought to correlate the hypermutation level of the proviral sequences in clinical samples with demographic variables, HIV-1 RNA viral load, and the level of CD4(+) T cells. Nested touchdown polymerase chain reaction (PCR) was performed with specific primers to detect hypermutation in the region of HIV-1 integrase, and the amplified sequences were run in agarose gels with HA-Yellow. The analysis of gel migration patterns using the k-means clustering method was validated by its agreement with the results obtained with the software Hypermut. Hypermutation was found in 31.2% of the investigated samples, and a correlation was observed between higher hypermutation levels and higher viral load levels. These findings suggest a high frequency of hypermutation detection in a Brazilian cohort, which can reflect a particular characteristic of this population, but also can result from the method approach by aiming at hypermutation-sensitive sites. Furthermore, we found that hypermutation events are pervasive during HIV-1 infection as a consequence of high viral replication, reflecting its role during disease progression.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25065371      PMCID: PMC4151062          DOI: 10.1089/AID.2013.0241

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  59 in total

1.  Error catastrophe and antiviral strategy.

Authors:  Manfred Eigen
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

2.  Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation.

Authors:  Craig Pace; Jean Keller; David Nolan; Ian James; Silvana Gaudieri; Corey Moore; Simon Mallal
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

3.  Loci polymorphisms of the APOBEC3G gene in HIV type 1-infected Brazilians.

Authors:  Maria Clara Bizinoto; Elcio Leal; Ricardo Sobhie Diaz; Luiz Mário Janini
Journal:  AIDS Res Hum Retroviruses       Date:  2010-09-28       Impact factor: 2.205

4.  Multiple sequence alignment using ClustalW and ClustalX.

Authors:  Julie D Thompson; Toby J Gibson; Des G Higgins
Journal:  Curr Protoc Bioinformatics       Date:  2002-08

5.  Deoxyribonucleoside triphosphate pool imbalances in vivo are associated with an increased retroviral mutation rate.

Authors:  J G Julias; V K Pathak
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

6.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.

Authors:  L M Mansky; H M Temin
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

7.  Analysis of a large collection of natural HIV-1 integrase sequences, including those from long-term nonprogressors.

Authors:  L M Skinner; S L Lamers; J C Sanders; M E Eyster; M M Goodenow; M Katzman
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-10-01

8.  Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant.

Authors:  Sandrine Opi; Sandra Kao; Ritu Goila-Gaur; Mohammad A Khan; Eri Miyagi; Hiroaki Takeuchi; Klaus Strebel
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

9.  APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenon.

Authors:  Andrew E Armitage; Koen Deforche; Chih-Hao Chang; Edmund Wee; Beatrice Kramer; John J Welch; Jan Gerstoft; Lars Fugger; Andrew McMichael; Andrew Rambaut; Astrid K N Iversen
Journal:  PLoS Genet       Date:  2012-03-22       Impact factor: 5.917

10.  Polymorphisms of CUL5 are associated with CD4+ T cell loss in HIV-1 infected individuals.

Authors:  Ping An; Priya Duggal; Li Hua Wang; Stephen J O'Brien; Sharyne Donfield; James J Goedert; John Phair; Susan Buchbinder; Gregory D Kirk; Cheryl A Winkler
Journal:  PLoS Genet       Date:  2007-01-26       Impact factor: 5.917

View more
  3 in total

1.  Impact of Suboptimal APOBEC3G Neutralization on the Emergence of HIV Drug Resistance in Humanized Mice.

Authors:  Matthew M Hernandez; Audrey Fahrny; Ravi Sachidanandam; Roberto F Speck; Viviana Simon; Anitha Jayaprakash; Gustavo Gers-Huber; Marsha Dillon-White; Annette Audigé; Lubbertus C F Mulder
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

2.  Pace of Coreceptor Tropism Switch in HIV-1-Infected Individuals after Recent Infection.

Authors:  Muhammad Shoaib Arif; James Hunter; Ana Rachel Léda; Jean Paulo Lopes Zukurov; Sadia Samer; Michelle Camargo; Juliana Galinskas; Esper Georges Kallás; Shirley Vasconcelos Komninakis; Luiz Mario Janini; Maria Cecilia Sucupira; Ricardo Sobhie Diaz
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

3.  Reduced HIV-1 latent reservoir outgrowth and distinct immune correlates among women in Rakai, Uganda.

Authors:  Jessica L Prodger; Adam A Capoferri; Katherine Yu; Jun Lai; Steven J Reynolds; Jingo Kasule; Taddeo Kityamuweesi; Paul Buule; David Serwadda; Kyungyoon J Kwon; Katherine Schlusser; Craig Martens; Eileen Scully; Yun-Hee Choi; Andrew D Redd; Thomas C Quinn
Journal:  JCI Insight       Date:  2020-07-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.